Plain-English translation of NCT07568678 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Type 2 Diabetes research guide →Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is an early-stage study testing a new medication called for people with type 2 diabetes. Researchers want to understand how safe the medication is, how the body handles it, and how it affects blood sugar levels. About 40 people will take different doses of the medication or a placebo (a fake pill with no active ingredient) to help answer these questions.
Type 2 diabetes affects millions of people, and doctors are always looking for new treatment options that work better or have fewer side effects. This medication represents a new approach, and this trial is an early step to see whether it could become a helpful option for patients.
You likely qualify if…
You likely don't qualify if…
You will visit the research clinic multiple times. At each visit, you will take either the new medication or a placebo at a specific dose, and researchers will monitor you with blood tests, heart monitoring, and vital sign checks. The study is designed in "doses that go up," meaning later groups of participants will receive higher amounts of the medication than earlier groups — this helps doctors find the safest and most effective dose. You won't know whether you're taking the real medication or placebo, and neither will the research team, which helps ensure fair results.
AI-generated summary from trial data · Jun 22, 2026 · Not medical advice
United States
Phase
Safety & dosing
Sponsor
Hua Medicine Limited
Collaborators
TigerMed
Enrollment target
~40 participants
Started
December 2025
Primary completion
August 2026
Age range
18 Years – 65 Years
Last updated on clinicaltrials.gov in May 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Jesus Olivia
Hua Medicine Limited
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.